Updates on Diagnosis and Treatment of PIK3CA-Related Overgrowth Spectrum
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Updates on Diagnosis and Treatment of PIK3CA-Related Overgrowth Spectrum
Authors
Keywords
-
Journal
ANNALS OF PLASTIC SURGERY
Volume Publish Ahead of Print, Issue -, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-02-03
DOI
10.1097/sap.0000000000003389
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Alpelisib to treat CLOVES syndrome, a member of the PIK3CA‐related overgrowth syndrome spectrum
- (2022) Gemma Garreta Fontelles et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib
- (2022) Gabriel Morin et al. JOURNAL OF EXPERIMENTAL MEDICINE
- At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
- (2022) Neil Vasan et al. Nature Reviews Clinical Oncology
- Somatic non-cancerous PIK3CA-related overgrowth syndrome treated with alpelisib in North America
- (2021) Alexandre P. Garneau et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- The role of the PIK3CA gene in the development and aging of the brain
- (2021) Shaozhen Xie et al. Scientific Reports
- Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome
- (2021) Karina Forde et al. Orphanet Journal of Rare Diseases
- A standard of care for individuals with PIK3CA ‐related disorders: An international expert consensus statement
- (2021) Sofia Douzgou et al. CLINICAL GENETICS
- Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel–Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study
- (2021) M. Luu et al. GENETICS IN MEDICINE
- A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations
- (2021) Guillaume Canaud et al. Orphanet Journal of Rare Diseases
- Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations
- (2021) Pascal Brouillard et al. Orphanet Journal of Rare Diseases
- RTK-dependent inducible degradation of mutant PI3Kα drives GDC-0077 (Inavolisib) efficacy
- (2021) Kyung W Song et al. Cancer Discovery
- PIK3CA-Related Overgrowth Spectrum From Diagnosis to Targeted Therapy: A Case of CLOVES Syndrome Treated With Alpelisib
- (2021) Angelica Pagliazzi et al. Frontiers in Pediatrics
- Case report: five-year experience of AKT inhibition with miransertib (MK-7075) in an individual with Proteus syndrome
- (2021) Christopher A. Ours et al. Cold Spring Harbor Molecular Case Studies
- Bleomycin Polidocanol Foam (BPF) Stability – In Vitro Evidence for the Effectiveness of a Novel Sclerosant for Venous Malformations
- (2020) Yi Sun et al. EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY
- A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity
- (2020) Eleftherios Kostaras et al. BRITISH JOURNAL OF CANCER
- Interim results of bleomycin-polidocanol foam sclerotherapy as a highly efficient technique for venous malformations
- (2020) Xi Yang et al. Journal of Vascular Surgery-Venous and Lymphatic Disorders
- Activating PIK3CA mutation promotes osteogenesis of bone marrow mesenchymal stem cells in macrodactyly
- (2020) Hengqing Cui et al. Cell Death & Disease
- Activating PIK3CA mutation promotes adipogenesis of adipose-derived stem cells in macrodactyly via up-regulation of E2F1
- (2020) Bin Sun et al. Cell Death & Disease
- Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation
- (2020) Ines Martinez-Corral et al. Nature Communications
- Rapamycin and treatment of venous malformations
- (2019) Emmanuel Seront et al. CURRENT OPINION IN HEMATOLOGY
- In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)
- (2018) C. Ranieri et al. NEUROGENETICS
- PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations
- (2018) Laura di Blasio et al. Cell Death & Disease
- Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum
- (2018) Victoria E. R. Parker et al. GENETICS IN MEDICINE
- Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
- (2018) Benjamin D. Hopkins et al. NATURE
- Targeted therapy in patients with PIK3CA-related overgrowth syndrome
- (2018) Quitterie Venot et al. NATURE
- Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer
- (2018) Anupam Batra et al. EXPERT OPINION ON EMERGING DRUGS
- Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly
- (2018) Lara Rodriguez-Laguna et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies
- (2016) Kim M. Keppler-Noreuil et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS
- Sirolimus for the treatment of children with various complicated vascular anomalies
- (2015) Herwig Lackner et al. EUROPEAN JOURNAL OF PEDIATRICS
- Lymphatic and Other Vascular Malformative/Overgrowth Disorders Are Caused by Somatic Mutations in PIK3CA
- (2015) Valerie L. Luks et al. JOURNAL OF PEDIATRICS
- Regulation of mTORC1 by PI3K signaling
- (2015) Christian C. Dibble et al. TRENDS IN CELL BIOLOGY
- PIK3CA Activating Mutations in Facial Infiltrating Lipomatosis
- (2013) Reid A. Maclellan et al. PLASTIC AND RECONSTRUCTIVE SURGERY
- Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA
- (2012) Marjorie J Lindhurst et al. NATURE GENETICS
- De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes
- (2012) Jean-Baptiste Rivière et al. NATURE GENETICS
- De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly
- (2012) Jeong Ho Lee et al. NATURE GENETICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search